Results 61 to 70 of about 9,015 (261)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

open access: yesInternational Journal of Pediatrics, 2014
Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV ...
Nusrat Homaira   +3 more
doaj   +1 more source

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil

open access: yesBMC Pediatrics, 2019
Background Palivizumab prophylaxis for the human respiratory syncytial virus (HRSV) has been reported to reduce the risk of hospital admissions related to HRSV in children with congenital heart disease (CHD). These children are at high risk of developing
Roseane Porfírio de Souza   +3 more
doaj   +1 more source

Passive Immunization in the Prevention and Treatment of Viral Infections

open access: yesEuropean Journal of Immunology, Volume 55, Issue 5, May 2025.
The development of new technologies for generating monoclonal antibodies has made it possible to extend the use of monoclonal antibodies for controlling viral infections. Here, we discuss the advances in antibody cloning techniques and the current use of passive immunization both as a preventative measure and treatment of viral infection.
Romila Moirangthem, Yotam Bar‐On
wiley   +1 more source

The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab – validation against two external data sources

open access: yesClinical Epidemiology, 2015
Ann Haerskjold,1,2 Lonny Henriksen,2 Susanne Way,1 Mikkel Malham,3 Jesper Hallas,4 Lars Pedersen,5 Lone Graff Stensballe1 1The Child and Adolescent Clinic 4072, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 2The Research Unit Women&#
Haerskjold A   +6 more
doaj  

Bronchiolitis: an update on management and prophylaxis. [PDF]

open access: yes, 2019
Bronchiolitis is an acute respiratory illness that is the leading cause of hospitalization in young children less than 2 years of age in the UK. Respiratory syncytial virus is the most common virus associated with bronchiolitis and has the highest ...
Bergroth E   +38 more
core   +1 more source

Disease Burden of RSV Infection in Adult Patients in Comparison to Influenza Virus Infection

open access: yesJournal of Medical Virology, Volume 97, Issue 5, May 2025.
ABSTRACT Respiratory Syncytial Virus (RSV) is well known for its impact on children, but its burden in adults remains underexplored, partly due to limited PCR testing before the COVID‐19 pandemic. In this study, the medical burden of RSV infections in adults was retrospectively investigated using 6‐year longitudinal data from a university hospital in ...
Georgii Trifonov   +8 more
wiley   +1 more source

Palivizumab

open access: yes, 2018
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
openaire   +2 more sources

Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update for 2021–2022

open access: yesMass Spectrometry Reviews, Volume 44, Issue 3, Page 213-453, May/June 2025.
Abstract The use of matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this review is the 12th update of the original article published in 1999 and brings coverage of the literature to the end of 2022.
David J. Harvey
wiley   +1 more source

Caratteristiche farmacologiche e uso clinico del Palivizumab nel trattamento dell’infezione dal virus respiratorio sinciziale [PDF]

open access: yes, 2016
Uno dei principali patogeni del tratto inferiore respiratorio nei bambini sotto i 2 anni è il virus respiratorio sinciziale (RSV). Nel 2015 fu stimato dall’OMS che erano presenti circa 64 milioni di infezioni l’anno e 160mila morti in tutto il mondo ...
SASSETTI, FILIPPO
core  

EDP‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults

open access: yesClinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT Respiratory syncytial virus (RSV) remains a significant health concern, particularly for vulnerable populations. Despite preventive strategies, there remains a need for effective antiviral treatments. EDP‐323 is a first‐in‐class, potent oral selective non‐nucleoside inhibitor of the large protein (L polymerase) of RSV under investigation for ...
Kimberly Elmore   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy